Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck on Pace for Largest Percent Decrease Since October 2017 -- Data Talk

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2019 | 02:29pm EDT

Merck & Co., Inc. (MRK) is currently at $80.46, down $4.36, or 5.14%

-- Would be lowest close since June 3 when it closed at $80.26

-- On pace for largest percent decrease since Oct. 30, 2017, when it fell 6.06%

-- Earlier Thursday, Barron's reported stocks of pharmaceutical companies are falling because "investors are worried that the Trump administration's war to rein in drug prices is just heating up -- and that big pharma could be the next target"

-- Currently down four of the past five days

-- Currently down two consecutive days, down 5.19% over this period

-- Worst two-day stretch since the two days ending April 18 when it fell 5.63%

-- Down 4.04% month-to-date

-- Up 5.3% year-to-date

-- Down 10.4% from its all-time closing high of $89.80 on Nov. 29, 2000

-- Up 28.41% from 52 weeks ago (July 12, 2018), when it closed at $62.66

-- Down 7.41% from its 52-week closing high of $86.90 on July 3

-- Up 28.72% from its 52-week closing low of $62.51 on July 19, 2018

-- Traded as low as $80.45; lowest intraday level since June 4 when it hit $80.11

-- Down 5.15% at Thursday's intraday low; largest intraday percent decrease since Oct. 25, 2018, when it fell as much as 6.29%

-- Worst performer in the DJIA Thursday

-- Second-worst performer in the S&P 500 Thursday

-- Subtracted 29.56 points from the DJIA so far Thursday

All data as of 1:59 p.m. EDT

Source: Dow Jones Market Data, FactSet

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 0.07% 27171.9 Delayed Quote.16.40%
MERCK AND COMPANY -0.22% 81.21 Delayed Quote.6.52%
NASDAQ 100 0.90% 7905.119269 Delayed Quote.24.87%
NASDAQ COMP. 0.71% 8204.137338 Delayed Quote.23.36%
S&P 500 0.28% 2985.03 Delayed Quote.18.74%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
04:31pSURE PETCARE : Launches SureFeed® Microchip Pet Feeder Connect
BU
10:18aMERCK AND : Bayer sells Dr. Scholl's footcare brand to Yellow Wood Partners
RE
06:52aBAYER COULD BENEFIT FROM HOME ADVANT : experts
RE
07/18MERCK AND : FDA Approves Merck's RECARBRIO For the Treatment of Adults with Comp..
AQ
07/18Intermolecular Stockholders Agree to Merck KGaA Acquisition
DJ
07/17AYTU BIOSCIENCE'S "BIG 4" : Natesto®, Tuzistra® XR, ZolpiMist(TM), And MiOXSYS® ..
AQ
07/17The end of inflated pharma pricing?
07/17MERCK AND : Bacterial-Infection Drug Recarbrio Approved by FDA
DJ
07/17MERCK AND : FDA Approves Merck's RECARBRIO™ (imipenem, cilastatin, and rel..
BU
07/16TRACKINSIGHT : No limit! S&P500, DJIA and Nasdaq Composite hitting new highs
TI
More news
Financials (USD)
Sales 2019 44 670 M
EBIT 2019 15 116 M
Net income 2019 10 053 M
Debt 2019 18 019 M
Yield 2019 2,73%
P/E ratio 2019 20,2x
P/E ratio 2020 16,5x
EV / Sales2019 5,09x
EV / Sales2020 4,76x
Capitalization 210 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 92,63  $
Last Close Price 81,39  $
Spread / Highest target 22,9%
Spread / Average Target 13,8%
Spread / Lowest Target 4,44%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY6.52%209 550
JOHNSON & JOHNSON0.98%345 980
PFIZER-2.02%237 451
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
NOVARTIS24.78%216 273